These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 31584195)
1. A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. Jack S; Madhivanan K; Ramadesikan S; Subramanian S; Edwards DF; Elzey BD; Dhawan D; McCluskey A; Kischuk EM; Loftis AR; Truex N; Santos M; Lu M; Rabideau A; Pentelute B; Collier J; Kaimakliotis H; Koch M; Ratliff TL; Knapp DW; Aguilar RC Int J Cancer; 2020 Jan; 146(2):449-460. PubMed ID: 31584195 [TBL] [Abstract][Full Text] [Related]
2. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Yang X; Kessler E; Su LJ; Thorburn A; Frankel AE; Li Y; La Rosa FG; Shen J; Li CY; Varella-Garcia M; Glodé LM; Flaig TW Clin Cancer Res; 2013 Jan; 19(1):148-57. PubMed ID: 23172881 [TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer. Masilamani AP; Fischer A; Schultze-Seemann S; Kuckuck I; Wolf I; Dressler FF; Gratzke C; Wolf P Anticancer Res; 2021 Aug; 41(8):3741-3746. PubMed ID: 34281832 [TBL] [Abstract][Full Text] [Related]
4. Tumor Targeting and Drug Delivery by Anthrax Toxin. Bachran C; Leppla SH Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376328 [TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin. Jinno H; Ueda M; Ozawa S; Kikuchi K; Ikeda T; Enomoto K; Kitajima M Cancer Chemother Pharmacol; 1996; 38(4):303-8. PubMed ID: 8674151 [TBL] [Abstract][Full Text] [Related]
6. Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer. Bue P; Holmberg AR; Márquez M; Westlin JE; Nilsson S; Malmström PU Eur Urol; 2000 Nov; 38(5):584-9. PubMed ID: 11096240 [TBL] [Abstract][Full Text] [Related]
7. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo. Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. Munk M; Memon AA; Nexo E; Sorensen BS BJU Int; 2007 Jan; 99(1):196-201. PubMed ID: 17092291 [TBL] [Abstract][Full Text] [Related]
9. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Bellmunt J; Hussain M; Dinney CP Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530 [TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits epidermal growth factor receptor signaling pathway activation and induces apoptosis in bladder cancer cells in vitro and in vivo. Chang L; Xiao W; Yang Y; Li H; Xia D; Yu G; Guo X; Guan W; Hu Z; Xu H; Zhuang Q; Ye Z Urol Oncol; 2014 Jan; 32(1):36.e11-8. PubMed ID: 23948182 [TBL] [Abstract][Full Text] [Related]
11. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799 [TBL] [Abstract][Full Text] [Related]
13. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors. Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419 [TBL] [Abstract][Full Text] [Related]
14. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Matsui Y; Hadaschik BA; Fazli L; Andersen RJ; Gleave ME; So AI Mol Cancer Ther; 2009 Aug; 8(8):2402-11. PubMed ID: 19625496 [TBL] [Abstract][Full Text] [Related]
15. HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7. Cao L; Li Q; Tong Z; Xing Y; Xu K; Yijia Wang J; Li W; Zhao J; Zhao L; Hong Z Int J Pharm; 2020 Jan; 574():118939. PubMed ID: 31836485 [TBL] [Abstract][Full Text] [Related]
20. In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. Sarosdy MF; Hutzler DH; Yee D; von Hoff DD J Urol; 1993 Dec; 150(6):1950-5. PubMed ID: 8230543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]